Ponatynib w leczeniu przewlekłej białaczki szpikowej i ostrej białaczki limfoblastycznej z chromosomem Filadelfia
Publication date: Available online 22 April 2016 Source:Acta Haematologica Polonica Author(s): Tomasz Sacha Ponatinib is a third generation tyrosine kinase inhibitor (TKI) active against wild type and mutant bcr/abl tyrosine kinase (including T315I). Ponatinib is approved for the treatment of adult patients with T315I mutation detected in CML (all phases) and in Ph+ ALL, for CML patients who are resistant to dasatinib or nilotinib and patients with Ph+ ALL who are intolerant or resistant to dasatinib and for whom subsequent imatinib treatment is not an optimal therapy. In phase II registration study (PACE), 267 patie...
Source: Acta Haematologica Polonica - April 22, 2016 Category: Hematology Source Type: research
Effective pain reduction during bone marrow biopsy and aspiration – Technique over experience
Conclusions: The differences in the pain scores between the doctors are most likely caused by differences in technique of BMBA. The analysis of the individual technique of the doctors performing the least painful biopsies may give answers needed for educational intervention aimed at pain reduction during BMBA. (Source: Acta Haematologica Polonica)
Source: Acta Haematologica Polonica - April 19, 2016 Category: Hematology Source Type: research
Metformina: stary lek w nowej aplikacji
Publication date: Available online 20 April 2016 Source:Acta Haematologica Polonica Author(s): Anna Dmoszyńska, Monika Podhorecka, Krzysztof Giannopoulos Metformin is a biguanide derivative that was synthesized in the 20thies years of last century. The main mechanism of action is the ability to inhibit hepatic gluconeogenesis and trigger glucose uptake in skeletal muscles. Metformin is not only an antihyperglycaemic drug but also has protective effects on endothelium cells. In the last decade, many publications displayed that metformin can reduce risk of cancer in diabetic patients and demonstrated a protective ...
Source: Acta Haematologica Polonica - April 19, 2016 Category: Hematology Source Type: research
Zmiany rodzaju koncentratu czynnika krzepnięcia u chorego na hemofilię – korzyść czy ryzyko?
Publication date: Available online 19 March 2016 Source:Acta Haematologica Polonica Author(s): Anna Klukowska Patients with haemophilia are treated with a variety of coagulation factor concentrates. They usually change concentrate types many times during their lifetime for different, often independent, reasons. Since recombinant coagulation factor concentrates VIII and IX became available, some patients in well-developed countries have started using these products instead of previously applied plasma-derived concentrates. At the moment, there are different types of concentrates available, including first, second and ...
Source: Acta Haematologica Polonica - March 19, 2016 Category: Hematology Source Type: research
Zmiany białaczkowe w ośrodkowym układzie nerwowym w przebiegu przewlekłej białaczki limfocytowej
Publication date: Available online 2 February 2016 Source:Acta Haematologica Polonica Author(s): Ewa Wąsik-Szczepanek, Dariusz Szczepanek, Małgorzata Wach, Marek Hus Central nervous system involvement (CNS) of chronic lymphocytic leukemia (CLL) is a rare complication. Some analyses of autopsy studies suggest that the complication remains subclinical or is under-diagnosed. The symptoms of patients with leukemic CNS involvement are heterogeneous and nonspecific. Due to the low incidence, there are no treatment guidelines for this problem. Intrathecal chemotherapy and cranial irradiation are often performed. (So...
Source: Acta Haematologica Polonica - February 23, 2016 Category: Hematology Source Type: research
Elevated factor VIII activity and venous thromboembolism in patients referred to the Iranian Blood Transfusion Organization: A case control study
Conclusion Elevated factor VIII is likely to be a risk factor for VTE. Moreover, a new normal reference range for the Iranian population was defined. (Source: Acta Haematologica Polonica)
Source: Acta Haematologica Polonica - February 23, 2016 Category: Hematology Source Type: research
Limfohistiocytoza hemofagocytarna związana z infekcją – opis przypadku
Publication date: Available online 19 February 2016 Source:Acta Haematologica Polonica Author(s): Karolina Torba, Grzegorz Helbig, Krzysztof Woźniczka, Anna Wacławik, Sławomira Kyrcz-Krzemień Hemophagocytic lymphohistiocytosis (HLH) is a rare and potentially fatal disorder characterized by abnormal activation of macrophages. It is also characterized by hemophagocytosis in the bone marrow and in the reticuloendothelial system (RES). The most common symptoms are persistent fever, splenomegaly and cytopenia. The probable mechanism of disease is due to hyperinflammation caused by increasing amounts of proinfl...
Source: Acta Haematologica Polonica - February 23, 2016 Category: Hematology Source Type: research
Alloprzeciwciała odpornościowe anty-C po transplantacji krwiotwórczych komórek macierzystych
Publication date: Available online 25 November 2015 Source:Acta Haematologica Polonica Author(s): Lucyna Pawelec-Marzec, Małgorzata Szymczyk-Nużka After multiple transfusions of blood components the patient produced alloantibodies anti-C from the Rh blood group system. These antibodies were the reason of the lack of compatibility of red blood cells of donor's hematopoietic stem cells. After allogeneic hematopoietic stem cell transplantation (allo-HSCT) the presence of anti-C from the Rh group was observed, which may indicate production of these antibodies by residual donor lymphocytes. The presence of anti-c, and...
Source: Acta Haematologica Polonica - January 12, 2016 Category: Hematology Source Type: research
Wczesna diagnostyka i leczenie postaci opornych i nawrotowych klasycznego chłoniaka Hodgkina
Publication date: Available online 30 December 2015 Source:Acta Haematologica Polonica Author(s): Jan Maciej Zaucha, Andrzej Deptała, Renata Zaucha Although the prognosis of Hodgkin's lymphoma (HL) is relatively good, about 10% of patients with early and up to 30% with advanced stages do not respond to first line treatment (ABVD) or relapse. The chemoresistance is defined as: the progression of the disease during treatment, lack of complete metabolic response during or after treatment, or the very early <3 months) relapse. At the time of relapse patients can be assigned to three risk groups: high, interme...
Source: Acta Haematologica Polonica - January 12, 2016 Category: Hematology Source Type: research
The patient with 5q minus syndrome and JAK2 V617F mutation with the presence of ringed erythroblasts meeting the criteria of RARS-T effectively treated with lenalidomide – A case report
We present the patient with 5q minus syndrome and JAK2 V617F mutation accompanied by the presence of ringed erythroblasts meeting the criteria of RARS-T. We could identify only two such patients reported in the literature; no details were given about effectiveness of lenalidomide in that group. We observed good response to the treatment with lenalidomide with transfusion independence 9 months after starting of the treatment; however, there was no complete eradication of del (5)(q13q31) clone nor the clone with JAK V617F mutation. (Source: Acta Haematologica Polonica)
Source: Acta Haematologica Polonica - January 12, 2016 Category: Hematology Source Type: research
Monoklonalne przeciwciała w szpiczaku plazmocytowym – przełom w terapii
Publication date: Available online 19 November 2015 Source:Acta Haematologica Polonica Author(s): Magdalena Olszewska-Szopa, Artur Jurczyszyn Myeloma multiplex (MM) is one of the most common haematological malignancies. In recent years, due to new drugs introduction, overall survival of the patients has improved very much. Nevertheless new active ingredients are being searched. There is growing attention to monoclonal antibodies. Over 20 molecules are being investigated, but none of them has already been approved in MM. Work on elotuzumab, daratumumab and in bone disease on denosumab is the most advanced. In this a...
Source: Acta Haematologica Polonica - November 21, 2015 Category: Hematology Source Type: research
Analiza leczenia nawrotowych i opornych postaci szpiczaka plazmocytowego wśród polskich pacjentów
This study summarizes therapeutic strategies used to treat recurrent plasma cell myeloma in Polish population before 2015, when bortezomib has become available in the first-line therapy. We focused mainly on the use of IMiDs and proteasome inhibitors. To analyze the situation medical records of patients treated in 21 Polish hematological centers have been reviewed. In total data on 400 patients were analyzed and extrapolated to the national level to obtain data on 7293 patients (400/7293). Mean number of applied therapies was 1.7. Half of the patients were treated with two or more chemotherapy regimens. Second-line therapy...
Source: Acta Haematologica Polonica - November 21, 2015 Category: Hematology Source Type: research
Mutacje TP53 w nowotworach hematologicznych
Publication date: Available online 19 November 2015 Source:Acta Haematologica Polonica Author(s): Małgorzata Zając, Krzysztof Giannopoulos The tumor suppressor p53 plays a crucial role in regulation of cell proliferation and maintaining integrity of the genome in human tissue. TP53 mutations are found in about 50% of solid tumors; however, hematological malignancies present a lower incidence of alteration in this gene. Within this group of patients, mutations of TP53 and 17p deletion are associated with poor prognosis and resistance to standard chemotherapy. During the past few years, treatment of patients with T...
Source: Acta Haematologica Polonica - November 21, 2015 Category: Hematology Source Type: research
Przyczyny dyskwalifikacji niespokrewnionych dawców krwiotwórczych komórek macierzystych
Conclusion The percentages of permanent deferrals are low in Polish donors. The temporal deferrals are mostly based on suspicion of infectious diseases. The temporal deferrals of over 3 weeks in most of the cases effectively block the donation possibility. (Source: Acta Haematologica Polonica)
Source: Acta Haematologica Polonica - November 18, 2015 Category: Hematology Source Type: research
Terapia metronomiczna w hematoonkologii: nadzieje i fakty
Publication date: Available online 6 November 2015 Source:Acta Haematologica Polonica Author(s): Anna Dmoszyńska, Elżbieta Starosławska, Krzysztof Giannopoulos In this article we have reviewed present publications concerning metronomic therapy. In contrast to standard chemotherapy, metronomic chemotherapy is characterized by the administration of cytotoxic agents at a much lower dose given at regular, but more frequent time intervals. This mode of administration may have different mechanisms of action but first of all it is thought to inhibit tumour angiogenesis. In this article, main mechanisms of action of m...
Source: Acta Haematologica Polonica - November 6, 2015 Category: Hematology Source Type: research
